Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia ; volume:15 ; number:6 ; day:12 ; month:6 ; year:2024 ; pages:1-11 ; date:6.2024
Cell death & disease ; 15, Heft 6 (12.6.2024), 1-11, 6.2024
- Urheber
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41419-024-06810-7
- URN
-
urn:nbn:de:101:1-2408182107509.844071804530
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:45 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Nwosu, Gus O.
- Ross, David M.
- Powell, Jason A.
- Pitson, Stuart M.
- SpringerLink (Online service)
Ähnliche Objekte (12)
RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax
Identifying mechanisms of resistance to BCL2 inhibitor venetoclax in acute myeloid leukemia (AML)
Investigation of resistance mechanisms in acute myeloid leukaemia towards tyrosine kinase inhibitors with mass spectrometry
Potential mechanisms of resistance to venetoclax and strategies to circumvent it
Combination strategies to overcome drug resistance in FLT+ acute myeloid leukaemia
Acute Myeloid Leukaemia in Its Niche: the Bone Marrow Microenvironment in Acute Myeloid Leukaemia
NL101 synergizes with the BCL-2 inhibitor venetoclax through PI3K-dependent suppression of c-Myc in acute myeloid leukaemia
FUS-ERG induces late-onset azacitidine resistance in acute myeloid leukaemia cells
Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells
Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells
A novel small molecule RAD51 inactivator overcomes imatinib‐resistance in chronic myeloid leukaemia
Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia
RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax
Identifying mechanisms of resistance to BCL2 inhibitor venetoclax in acute myeloid leukemia (AML)
Investigation of resistance mechanisms in acute myeloid leukaemia towards tyrosine kinase inhibitors with mass spectrometry
Potential mechanisms of resistance to venetoclax and strategies to circumvent it
Combination strategies to overcome drug resistance in FLT+ acute myeloid leukaemia
Acute Myeloid Leukaemia in Its Niche: the Bone Marrow Microenvironment in Acute Myeloid Leukaemia
NL101 synergizes with the BCL-2 inhibitor venetoclax through PI3K-dependent suppression of c-Myc in acute myeloid leukaemia
FUS-ERG induces late-onset azacitidine resistance in acute myeloid leukaemia cells
Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells
Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells
A novel small molecule RAD51 inactivator overcomes imatinib‐resistance in chronic myeloid leukaemia
Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia
RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax
Identifying mechanisms of resistance to BCL2 inhibitor venetoclax in acute myeloid leukemia (AML)
Investigation of resistance mechanisms in acute myeloid leukaemia towards tyrosine kinase inhibitors with mass spectrometry
Potential mechanisms of resistance to venetoclax and strategies to circumvent it
Combination strategies to overcome drug resistance in FLT+ acute myeloid leukaemia
Acute Myeloid Leukaemia in Its Niche: the Bone Marrow Microenvironment in Acute Myeloid Leukaemia
NL101 synergizes with the BCL-2 inhibitor venetoclax through PI3K-dependent suppression of c-Myc in acute myeloid leukaemia
FUS-ERG induces late-onset azacitidine resistance in acute myeloid leukaemia cells
Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells
Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells
A novel small molecule RAD51 inactivator overcomes imatinib‐resistance in chronic myeloid leukaemia